| Bioactivity | KNa1.1-IN-2 (Compound Z05) is a selective KNa1.1 channel inhibitor with blood-brain barrier penetration, particularly effective against the hERG channel. KNa1.1-IN-2 works by binding to the KNa1.1 channel and blocking the channel activity induced by Gain-of-function (GOF) mutations, effectively intervening in KCNT1-related epilepsy. Additionally, KNa1.1-IN-2 inhibits the GOF mutant Y796H. KNa1.1-IN-2 holds promise for research into KCNT1-related epilepsy disorders[1]. |
| CAS | 3037315-44-6 |
| Formula | C24H27NO |
| Molar Mass | 345.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zheng R, et al. Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel. J Med Chem. 2024 Nov 14;67(21):19519-19545. |
KNa1.1-IN-2
CAS: 3037315-44-6 F: C24H27NO W: 345.48
KNa1.1-IN-2 (Compound Z05) is a selective KNa1.1 channel inhibitor with blood-brain barrier penetration, particularly ef
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.